Official: Pfizer and Allergan merger plan terminated

6 April 2016
mergers-acquisitions-big

Following frantic speculation since the USA announced new tax regulations aimed at preventing tax inversion orientated M&A activity, the biggest pharmaceutical acquisition deal in history, has been terminated.

As was widely forecast, US pharma giant Pfizer (NYSE: PFE) this morning announced that it will not proceed with its planned $160 billion acquisition of Ireland-domiciled Allergan (NYSE: AGN). This is Pfizer’s second aborted attempt at a tax-inversion directed acquisition; in 2014, after company and political objections, it gave up on its $69 billion (~$98 billion at current exchange rates) takeover of Anglo-Swedish pharma major AstraZeneca.

Pfizer’s shares rose 1% in pre-market opening trading in the USA, percent in trading before the, while Allergan declined less than 1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical